Exact Sciences Corp.
https://www.exactsciences.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Exact Sciences Corp.
Harbinger Health Raised $140M In Series B To Further Develop First Blood-Based Cancer Test
Harbinger Health has raised a total of $190m since its founding in 2021. Its CEO Stephen Hahn told Medtech Insight in March that the company plans to develop a blood-based cancer test that is affordable, accessible and also more accurate than currently available tests.
Companies Find Growth Opportunities In Maturing Colorectal Cancer Blood-Based Screening Market
Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.
HHS Watchdog Blesses Proposed Gift Card Giveaway To Encourage Test Returns
A proposal that would give some patients gift cards in exchange for returning a screening test sample would not violate anti-kickback law because it doesn’t encourage medically unnecessary services, HHS-OIG says.
Harbinger Health CEO Stephen Hahn On Early Cancer Detection To ‘Move The Needle’ On Survival
Medtech Insight spoke with Stephen Hahn, ex-FDA commissioner and CEO of Harbinger Health, who attended SXSW, about the firm’s blood-based cancer test in development.
Company Information
- Industry
- Biotechnology
- Laboratory Testing Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Base Genomics
- Genomic Health, Inc.
- Paradigm Diagnostics, Inc.
- Thrive Earlier Detection Corp.
- Viomics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice